Cargando…
Meta-analysis of the efficacy and safety of sintilimab for treating advanced non-small cell lung cancer
Lung cancer is the leading cause of death from malignant tumors in China, and non-small cell lung cancer (NSCLC) accounts for >80% of all types of lung cancer. Novel immunotherapeutic agents targeting programmed death protein-1 (PD-1) and its ligands [programmed death ligands (PD-L)1 and 2] have...
Autores principales: | Xie, Jiejie, Wu, Xueyan, Wu, Jianmei, Huang, Fang, Xu, Luning |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580245/ https://www.ncbi.nlm.nih.gov/pubmed/36284649 http://dx.doi.org/10.3892/ol.2022.13545 |
Ejemplares similares
-
Sintilimab for the treatment of non-small cell lung cancer
por: Zhang, Lin, et al.
Publicado: (2022) -
Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer: a prospective, single-arm, phase II study in China
por: Han, Xiao, et al.
Publicado: (2022) -
Safety and efficacy of sintilimab combination therapy for the treatment of 48 patients with advanced malignant tumors
por: Huang, Nana, et al.
Publicado: (2022) -
A retrospective cohort study of sintilimab and pembrolizumab as first-line treatments for advanced non-small cell lung cancer
por: Wu, Kai, et al.
Publicado: (2022) -
Effect of Sintilimab combined with Chemotherapy on Tumor Markers and Immune Function of advanced non-small cell lung cancer
por: Liang, Xiaoyan, et al.
Publicado: (2021)